Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761.

Fu,Y., Ponce,M.L., Thill,M., Yuan,P., Wang,N.S., and Csaky,K.G. 2007. Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761. Invest Ophthalmol. Vis. Sci. 48, 5184-5190.